Q2) What is the status of the HUMIRA launch?

     A2) Abbott began shipments of HUMIRA early in the first quarter, a little
         more than a week after its approval by the FDA. We are very pleased
         with the launch progress and continue to receive positive feedback
         from both patients and physicians. Prescription trends and market
         share growth have been strong, and more than 95 percent of all
         managed care organizations are now reimbursing for HUMIRA. Sales in
         the quarter totaled $26 million, including $24 million from the
         United States and $2 million in international sales from patient
         named basis (PNB) programs. Final European regulatory approval is
         pending.

         As a result of the prescription growth trends for HUMIRA, Abbott is
         raising its 2003 worldwide sales forecast for the drug from more than
         $150 million to more than $200 million, based on our recent U.S.
         launch and a European launch later this year. In 2004, we project
         worldwide sales in excess of $500 million, and we continue to
         forecast peak-year sales of more than $1 billion for the rheumatoid
         arthritis (RA) indication alone. As would be expected with any new
         drug the size of HUMIRA, we will invest heavily to ensure we realize
         its full commercial potential.  Since RA is just one of the many
         potential indications for HUMIRA, we are also pursuing five
         additional indications -- each with the commercial potential to add
         several hundred million dollars in incremental revenue to our
         $1 billion peak-year forecast for RA.  The company already has
         initiated trials in psoriasis, psoriatic arthritis, juvenile RA and
         Crohn's disease and expects to begin trials in ankylosing spondylitis
         in the coming months.